When can a risk factor be used as a worthwhile screening test?
about
Lung cancer susceptibility model based on age, family history and genetic variantsGenetic variation in an individual human exomeCirculating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysisGenetic testing and common disorders in a public health framework: how to assess relevance and possibilities. Background Document to the ESHG recommendations on genetic testing and common disordersRisk factor thresholds: their existence under scrutinyA strategy to reduce cardiovascular disease by more than 80%How is risk defined in high-risk surgical patient management?Genetics of coronary artery diseasePredictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysisScreening for future cardiovascular disease using age alone compared with multiple risk factors and ageIndividual and cumulative effects of GWAS susceptibility loci in lung cancer: associations after sub-phenotyping for COPDEvaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery diseasePerformance, treatment pathways, and effects of alternative policy options for screening for developmental dysplasia of the hip in the United Kingdom.Predicting late-onset sepsis by routine neonatal screening for colonisation by gram-negative bacteria in neonates at intensive care units: a protocol for a systematic reviewClinical utility of five genetic variants for predicting prostate cancer risk and mortality.Risk prediction models with incomplete data with application to prediction of estrogen receptor-positive breast cancer: prospective data from the Nurses' Health Study.Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts.The diagnosis of colorectal cancer in patients with symptoms: finding a needle in a haystack.None-endoscopic Screening for Esophageal Squamous Cell Carcinoma- A Review.Revisiting the discriminatory accuracy of traditional risk factors in preeclampsia screening.Appraising organised screening programmes for testing for genetic susceptibility to cancer.Applying measures of discriminatory accuracy to revisit traditional risk factors for being small for gestational age in Sweden: a national cross-sectional study.Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR).Derivation and validation of a risk-factor model for detection of oral potentially malignant disorders in populations with high prevalence.Early identification of cardiovascular risk using genomics and proteomics.Genetic associations in diabetic nephropathy: a meta-analysisEvaluation of a breast cancer risk prediction model expanded to include category of prior benign breast disease lesionBody mass index adjusted prostate-specific antigen and its application for prostate cancer screening.Screening for older emergency department inpatients at risk of prolonged hospital stay: the brief geriatric assessment tool.Patient-controlled encrypted genomic data: an approach to advance clinical genomics.Meta-analysis of the relationship between common type 2 diabetes risk gene variants with gestational diabetes mellitus.Association between obesity indices and cardiovascular risk factors in late adolescence in the Seychelles.Screening in early pregnancy for pre-eclampsia using Down syndrome quadruple test markers.A new electrocardiogram marker to identify patients at low risk for ventricular tachyarrhythmias: sum magnitude of the absolute QRST integral.What can be learnt from models of incidence rates?Fracture risk prediction using BMD and clinical risk factors in early postmenopausal women: sensitivity of the WHO FRAX toolPredictive value of updating Framingham risk scores with novel risk markers in the U.S. general population.Development and validation of a clinical score for prognosis stratification in patients requiring antiretroviral therapy in sub-Saharan Africa: a prospective open cohort study.Contributions of 18 additional DNA sequence variations in the gene encoding apolipoprotein E to explaining variation in quantitative measures of lipid metabolism.Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events.
P2860
Q21091204-EAEA272F-4D13-40E5-9C9B-CDFD962002A8Q21145035-3070D74B-56E0-49F0-ABDB-1A3F9D81456BQ22252898-836FF323-6B02-45F2-BD76-A8E9B64EB58AQ22330767-5A6D90BC-7779-4BF8-AAB0-DC72D9B6B24EQ24527206-584B4A6E-2375-455E-8F2C-FD2BF42566F2Q24679592-9AD16678-8E42-40D0-9324-1F6EA9008050Q24817019-0F547285-2483-4C87-B5C0-E698D35935BDQ26866396-29004861-23B0-4082-BBBB-50476CBD7D1BQ27000984-17E3BC0D-B5AB-4F7E-AB9B-C12AF37DFA6EQ28740466-123D19F2-E3CB-4E0D-A6ED-4348C0386256Q28743099-EEF0CCF4-89F6-4ED4-A07F-8FF2C22ABBB7Q28751824-EE2FB6BB-9D8A-4219-A3FC-B5F678E19819Q30478512-1A74717F-2690-4AF4-9BDB-89893246FE03Q30491272-38825321-C232-49CA-B0C9-91F68788577AQ30492173-F2BD7602-F5ED-4971-AD6F-896B3AC2C57AQ31161296-92C0381C-E8DD-48A0-A876-BFA03CC4F177Q33377856-029095F7-5304-42E1-875D-5E1B3D57B377Q33431443-2C105F7D-F4A9-449B-928A-F3420A50C976Q33597366-67A2628C-065F-4403-BC6D-EC76B17CCA80Q33728661-E715CBF4-2D93-44A0-84E0-FC6E48596342Q33805447-F31CB3FE-ECA4-45D3-919C-B70881F9BBFEQ33996015-2A559011-A171-41D4-B875-5C1588BF9C2BQ34039859-B6EB2AE9-7511-4C3E-83D7-105BA6297C1DQ34059743-0CBD9D4B-982B-44C1-A627-DE47AD3974B9Q34129889-A1F4071D-B7CF-40C1-A41D-43C916376A81Q34153165-7A4BFF17-7E98-4FD9-931B-0B75CA37DB30Q34234311-2F3FA869-65A1-426C-A9D9-0FA2DB8C7ED0Q34288514-EEE124CF-7607-4821-9F2D-CA357278D4F1Q34344014-E45A1875-16DF-4C7F-8E44-E2FFF7DD96A7Q34346566-3A2B0A04-13D7-491C-A12B-07F0FD6ADAB8Q34430295-2F42C91B-88FB-48EE-9273-2C076BFD1946Q34470162-9E18E26C-585C-4C32-A851-0E5D94D19AC3Q34525959-1E381840-5ECC-48EF-B432-DD81DA506B90Q34682684-41C60A3C-A784-4B8D-8B2E-BCBE2469DAADQ35012835-2E8F8C0F-347E-411C-9D7E-8732A8217213Q35037792-019FADBD-C65C-44C5-8B18-D0DF0F241ACBQ35099546-B949DD17-E9B2-4373-9AEC-EBAB6161F635Q35767307-E5E81E5D-81F8-44F7-8715-471EDDE1FAB5Q35834661-57F73F6B-6F54-44C5-AABD-152FAE7D6238Q35848788-9FC1365D-BF1A-44E6-B137-791D893C80C1
P2860
When can a risk factor be used as a worthwhile screening test?
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
When can a risk factor be used as a worthwhile screening test?
@ast
When can a risk factor be used as a worthwhile screening test?
@en
type
label
When can a risk factor be used as a worthwhile screening test?
@ast
When can a risk factor be used as a worthwhile screening test?
@en
prefLabel
When can a risk factor be used as a worthwhile screening test?
@ast
When can a risk factor be used as a worthwhile screening test?
@en
P2093
P1433
P1476
When can a risk factor be used as a worthwhile screening test?
@en
P2093
P304
P356
10.1136/BMJ.319.7224.1562
P407
P577
1999-12-01T00:00:00Z